The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
The investment in land is Rs. 19.85 crore
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
